4 May 2016 - CADTH has received notice of a pending submission from Teva Pharmaceuticals for reslizumab for use by patients with eosinopilic asthma.

The submission is due on 2 June 2016.

For more details, go to: https://www.cadth.ca/reslizumab?utm_source=%2ALIVE%2A+CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=f2f160c847-Call-for-PI-Reslizumab-5-04-2016&utm_medium=email&utm_term=0_2e3705996c-f2f160c847-262951505